Results 121 to 130 of about 1,341 (168)

Comparison of ophthalmic surgery rates in teprotumumab-treated vs. teprotumumab-untreated thyroid eye disease patients. [PDF]

Arq Bras Oftalmol
Linaburg TJ, Pradeep T, Rinelli B, Chen Y, Chen Y, Ying GS, Briceño CA, Tamhankar M.   +7 more
europepmc   +1 more source

A Nationwide Survey by the Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS) on the Management of Thyroid Eye Disease in South Korea. [PDF]

Korean J Ophthalmol
Surl D, Ko J, Yang J, Yoon JS.
europepmc   +1 more source

Management and presentation of pediatric thyroid eye disease: A systematic review and meta-analysis. [PDF]

Eur J Ophthalmol
Lai AC, Yu CW, Golrokhian-Sani AA, Morcos M, Hanna A, Heede S.   +5 more
europepmc   +1 more source

Extending the Graves' Triad: Thyroid Eye Disease, Dermopathy, and Acropachy: A Clinical Response to Teprotumumab. [PDF]

JCEM Case Rep
Lira J, Dixon P, Zaidi M, Kim SM.
europepmc   +1 more source

Management of Thyroid Eye Disease: A Comparison Between Three Recent Clinical Guidelines. [PDF]

Ophthalmol Ther
Lei C, Jin J, Li R, Yip CC, Chong KKL, Smith TJ, Sun J, Zhou H.   +7 more
europepmc   +1 more source

Abstracts of the EUGOGO Global TED Forum 2025. [PDF]

Thyroid Res
europepmc   +1 more source

Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 London. [PDF]

Eye (Lond)
Lee V, Salvi M, Eckstein A, Dayan C, Meeran K.   +4 more
europepmc   +1 more source

What has changed in thyroid eye disease in the last five years (2020-2025). [PDF]

Eur Thyroid J
Salvi M.
europepmc   +1 more source

Teprotumumab for treating active thyroid eye disease: A meta-analysis. [PDF]

Medicine (Baltimore)
Cong X, Pei L, Hu H.
europepmc   +1 more source

Sirolimus for the treatment of Graves' orbitopathy. [PDF]

Thyroid Res
Comi S, Sabini E, Cosentino G, Santini F, Marinò M.   +4 more
europepmc   +1 more source